Authors: AWADA A THODTMANN R PICCART MJ DIEU M BARTHOLOMEUS S HOPPENER F WANDERS J VONBROEN IM HANAUSKE AR

Citation: A. Awada et al., A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF LU-79553 ADMINISTEREDEVERY 21 OR 42 DAYS IN PATIENTS (PTS) WITH SOLID TUMORS - AN EORTC-ECSG STUDY, Annals of oncology, 9, 1998, pp. 470-470

Authors: THODTMANN R AWADA A PICCART M HOPPENER F WANDERS J VONBROEN IM HANAUSKE AR

Citation: R. Thodtmann et al., CLINICAL AND PHARMACOKINETIC EVALUATION OF THE NEW BISNAPHTALAMIDE LU-79553 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH SOLID TUMORS - AN EORTC ECSG STUDY/, European journal of cancer, 33, 1997, pp. 1106-1106

Authors: MROSS K FIEBIG HH BERDEL W BANKMANN Y VONBROEN IM WALTER N UNGER C

Citation: K. Mross et al., CLINICAL AND PHARMACOKINETIC PHASE-I STUDY WITH CEMATODIN(R) GIVEN ASCONTINUOUS 24-HOUR INTRAVENOUS-INFUSION, European journal of cancer, 33, 1997, pp. 1122-1122

Authors: MROSS K HERBST K BERDEL WE KORFEL A VONBROEN IM BANKMANN Y HOSSFELD DK

Citation: K. Mross et al., PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF LU103793 (CEMADOTIN HYDROCHLORIDE) AS AN INTRAVENOUS BOLUS INJECTION IN PATIENTS WITH METASTATIC SOLID TUMORS - A STUDY OF THE AIO PHASE-I AND APOH GROUP OF THE GERMAN-CANCER-SOCIETY, Onkologie, 19(6), 1996, pp. 490-495